- Abciximab (Reopro®), licensed in UK/EU for:
- Post angioplasty
- ACS
- Adalimumab (Humira®),licensed in UK/EU for:
- Alemtuzumab (MabCampath®), licensed in UK/EU for:
- Basiliximab (Simulect®), licensed in UK/EU to:
- Prevent acute organ rejection
- Bevacizumab (Avastin®), used in:
- Cancer chemotherapy
- Phase III Macular degeneration, diabetic proliferative retinopathy
- Cetuximab (Erbitux®), used in:
- EGFR expressing cancers
- Daclizumab (Zenapax®), licensed in UK/EU to:
- Prevent acute organ rejection
- Eculizumab in phase III trials:
- Complement inhibitor that works in paroxysmal nocturnal haemoglobinuria.
- Efalizumab (Raptiva®),licensed in UK/EU for:
- Moderate to severe chronic plaque psoriasis
- Gemtuzumab (Mylotarg®)
- Phase III acute myeloid leukaemia)
- Ibritumomab tiuxetan (Zevalin®)
- Infliximab (Remicade®), licensed in UK/EU for:
- Muronomab-CD3
- Omalizumab (Xolair®,licensed in UK/EU for:
- Convincing IgE mediated asthma
- Panitumumab - Developed to target:
- Against EGFR
- Palivizumab (Synagis®), licensed in UK/EU for:
- Prevention of respiratory syncytial virus (RSV) disease
- Ranibizumab (Lucentis®), used in:
- Phase III Macular degeneration, diabetic proliferative retinopathy
- Rituximab (Mabthera®, licensed in UK/EU for:
- Non-Hodgkin's lymphoma
- rheumatoid arthritis)
- Trastuzumab (Herceptin ®, licensed in UK/EU for:
- Early and metastatic breast cancer
- Tositumomab - Developed to target:
- CD20 antigen-expressing tumours with radionucleotide load
Category:Monoclonal antibodies
From Ganfyd
Entities in Class
Web Resources for Monoclonal antibodies
Relevant Clinical Literature
UK Guidance
See Wikipedia on monoclonal antibodies. Used as both drugs and diagnostic reagents. This is such a rapidly developing therapeutic field that there are major international differences in availability and licensed status of the various drugs. These drugs act on different proteins and are therefore not one class of drug at all. By 2006 there were well over 160 in clinical trials worldwide.
The INN names convey quite a lot about the antibody[1] vis:
| Prefix | Intended target when developed | Source of binding portion | Suffix | ||
|---|---|---|---|---|---|
| variable | -ba(c)- | bacterial | -a- | rat | -mab |
| -ci(r)- | cardiovascular | -e- | hamster | ||
| -co(l)- | colonic tumor | -i- | primate | ||
| -go(t)- | testicular tumor | -o- | mouse | ||
| -go(v)- | ovarian tumor | -u- | human | ||
| -le(s)- | infectious lesions | -xi- | chimeric | ||
| -li(m)- | immune modulating | -zu- | humanized | ||
| -ma(r)- | breast tumor | ||||
| -me(l)- | melanoma | ||||
| -pr(o)- | prostate tumor | ||||
| -tu(m)- | miscellaneous tumor | ||||
| -vi(r)- | viral | ||||
References
Pages in category "Monoclonal antibodies"
The following 28 pages are in this category, out of 28 total.
ABCD |
EFGIMN |
OPRTUV |
